Saved report copy
Recorded
Eli Lilly raises outlook after beating estimates on Zepbound, Mounjaro demand
Eli Lilly beat third-quarter expectations and raised its full-year 2026 revenue forecast to between $91 billion and $92 billion, up from $85 billion to $87 billion. Adjusted earnings were $7.48 per share on revenue of $24.40 billion, above analyst forecasts. Demand drove Mounjaro sales up 65% to $10.72 billion and Zepbound sales up 49% to $5.35 billion, though the new obesity pill Foundayo brought in $184 million, below expectations. The results show Lilly's GLP-1 franchise remains strong despite lower US prices and competition from Novo Nordisk.